Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics L...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and...
Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company pioneering transformative gene therapies...
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of...
Conduit Pharmaceuticals Inc. announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Com...
Synfini, Inc., a trailblazer in AI-driven chemistry automation, today announced a $8.9 million expansion of its round, led by JSL Health Capital and supp...
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGA...
The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or predn...
MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIE...
Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone paym...
Axplora is proud to unveil a transformative €35 million expansion at its Farmabios site in Gropello Cairoli, Italy, reinforcing the company&rsqu...
HUTCHMED (China) Limited announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISS...
ProtoBind-Diff generates drug-like molecules for specific protein targets using only their amino acid sequences—no 3D structures required. The m...
© 2025 Biopharma Boardroom. All Rights Reserved.
